Table 2 The number of patients in the study sample at each stage of the CrAg Screening Cascade, stratified by urban/rural status of the health facility where their record was reviewed and overall (n = 359)

Patients with CD4 ≤ 100 μ/ml

209 (58.2)

150 (41.8)

359 (100.0)

Patients with CrAg screen

170: 81.3 (75.4–86.4)

85: 56.7 (48.3–64.7)

255: 71.0 (66.0–75.7)

< 0.001

Patients screened for CrAg within 7 days of a CD4 test

138: 81.2 (74.5–86.8)

72: 84.7 (75.3–91.6)

210: 82.4 (53.4–63.8)

0.489

Patients with CrAg screen contacted with results

170: 100.0 (97.9–100.0)

82: 96.5 (90.0–99.3)

252: 98.8 (96.6–99.8)

0.014

Patients with a CrAg positive result

48: 28.2 (21.5–35.0)

8: 9.4 (4.2–17.7)

56: 22.0 (17.0–27.5)

0.001

Patients screen for signs and symptoms of CNS infection

43: 89.6 (77.3–96.5)

7: 87.5 (47.3–99.7)

50: 89.3 (78.1–96.0)

0.860

Patients in whom a lumbar puncture was done

39: 81.3 (67.4–91.1)

0: 0 (0.0–0.0)

39: 69.6 (55.9–81.2)

Patients started on pre-emptive fluconazole therapy

39: 81.3 (67.4–91.1)

8: 100.0 (63.1–100.0)

47: 83.9 (71.7–92.4)

0.181

Patients started on fluconazole that were still receiving pre-emptive fluconazole at 6 months

5: 12.8 (4.5–28.8)

3: 37.5 (8.5–75.5)

8: 17.0 (7.6–30.8)

0.108

Patients who were started on ART

183: 87.6 (82.3–91.7)

149: 99.3 (96.3–100.0)

332: 92.5 (89.2–95.0)

< 0.001

Patients who were started on ART prior to CrAg screening

130: 71.0 (63.9–77.5)

53: 35.6 (27.9–43.8)

129: 38.9 (33.6–44.3)

< 0.001

Patients with a CD4 ≤ 100 μ/ml that were reportedly alive at the time of data collection

110: 52.6 (45.6–59.6)

103: 68.7 (60.6–76.0)

213: 59.3 (54.1–64.5)

0.002